Shares of Catalyst Biosciences, Inc. (NASDAQ:CBIO) shot up 0.3% on Thursday . The company traded as high as $4.74 and last traded at $3.77. 524,525 shares were traded during mid-day trading, an increase of 90% from the average session volume of 276,416 shares. The stock had previously closed at $3.78.

A number of research firms recently weighed in on CBIO. Chardan Capital began coverage on shares of Catalyst Biosciences in a research report on Monday, June 12th. They issued a “buy” rating and a $10.00 price objective on the stock. Ladenburg Thalmann Financial Services began coverage on shares of Catalyst Biosciences in a research report on Tuesday, June 6th. They issued a “buy” rating and a $11.00 price objective on the stock. Finally, Zacks Investment Research lowered shares of Catalyst Biosciences from a “buy” rating to a “hold” rating in a research report on Monday, June 5th.

The stock’s market cap is $15.26 million. The firm has a 50 day moving average price of $3.64 and a 200-day moving average price of $4.87.

Catalyst Biosciences (NASDAQ:CBIO) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($2.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.46) by $1.07. Catalyst Biosciences had a negative return on equity of 92.61% and a negative net margin of 3,127.92%. The firm had revenue of $0.11 million for the quarter. On average, equities research analysts predict that Catalyst Biosciences, Inc. will post ($7.08) earnings per share for the current fiscal year.

A number of hedge funds have recently modified their holdings of the business. Dimensional Fund Advisors LP purchased a new position in Catalyst Biosciences during the second quarter worth about $372,000. Vanguard Group Inc. raised its stake in Catalyst Biosciences by 294.1% during the second quarter. Vanguard Group Inc. now owns 43,714 shares of the biopharmaceutical company’s stock worth $204,000 after purchasing an additional 32,621 shares during the period. Zacks Investment Management purchased a new position in Catalyst Biosciences during the second quarter worth about $147,000. Bank of New York Mellon Corp purchased a new position in Catalyst Biosciences during the second quarter worth about $107,000. Finally, Virtu KCG Holdings LLC purchased a new position in Catalyst Biosciences during the second quarter worth about $103,000. 29.21% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was posted by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another site, it was copied illegally and reposted in violation of United States & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dailypolitical.com/2017/09/09/catalyst-biosciences-inc-cbio-shares-up-0-3.html.

About Catalyst Biosciences

Catalyst Biosciences, Inc, formerly Targacept, Inc, is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.